Key result
Dihydroergocristine is linked to restored menstruation in ~66% of amenorrhoeic women and successful ovulation.
Why the study?
Does dihydroergocristine reduce serum prolactin and improve clinical symptoms in hyperprolactinaemic and puerperal women?
Population
40 hyperprolactinaemic women (29 with amenorrhoea) and an unspecified number of puerperal women.
Design
Case_series
Follow-up
10 days for puerperal women; unspecified for…
Authors
Loading...
May support use in hyperprolactinaemic amenorrhoea; leaves open need for randomized trials versus standard agents.
Does dihydroergocristine reduce serum prolactin and improve clinical symptoms in hyperprolactinaemic and puerperal women?
Dihydroergocristine may serve as an effective and well-tolerated alternative to standard dopaminergic drugs for lowering prolactin and restoring normal reproductive function in hyperprolactinaemic women.
Scarduelli et al. (1987) studied Hyperprolactinaemia and puerperal lactation (n=40). Dihydroergocristine was evaluated on Serum prolactin reduction, restoration of menstruation and ovulation, and prevention of lactation. Dihydroergocristine restored menstruation in 19 of 29 women with amenorrhoea, induced ovulation in 21 of 40 hyperprolactinaemic patients, and prevented puerperal lactation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: